Cargando…

Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases

Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Delbaere, Quentin, Chapet, Nicolas, Huet, Fabien, Delmas, Clément, Mewton, Nathan, Prunier, Fabrice, Angoulvant, Denis, Roubille, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865197/
https://www.ncbi.nlm.nih.gov/pubmed/36678575
http://dx.doi.org/10.3390/ph16010078
_version_ 1784875776621936640
author Delbaere, Quentin
Chapet, Nicolas
Huet, Fabien
Delmas, Clément
Mewton, Nathan
Prunier, Fabrice
Angoulvant, Denis
Roubille, François
author_facet Delbaere, Quentin
Chapet, Nicolas
Huet, Fabien
Delmas, Clément
Mewton, Nathan
Prunier, Fabrice
Angoulvant, Denis
Roubille, François
author_sort Delbaere, Quentin
collection PubMed
description Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disease by itself has led to the development of new treatments. In this article, we discuss the pathophysiology of inflammation and focus attention on therapeutics targeting different inflammatory pathways of atherosclerosis and myocardial infarction. In atherosclerosis, colchicine is included in new recommendations, and eight randomized clinical trials are testing new drugs in different inflammatory pathways. After a myocardial infarction, no drug has shown a significant benefit, but we present four randomized clinical trials with new treatments targeting inflammation.
format Online
Article
Text
id pubmed-9865197
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98651972023-01-22 Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases Delbaere, Quentin Chapet, Nicolas Huet, Fabien Delmas, Clément Mewton, Nathan Prunier, Fabrice Angoulvant, Denis Roubille, François Pharmaceuticals (Basel) Brief Report Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disease by itself has led to the development of new treatments. In this article, we discuss the pathophysiology of inflammation and focus attention on therapeutics targeting different inflammatory pathways of atherosclerosis and myocardial infarction. In atherosclerosis, colchicine is included in new recommendations, and eight randomized clinical trials are testing new drugs in different inflammatory pathways. After a myocardial infarction, no drug has shown a significant benefit, but we present four randomized clinical trials with new treatments targeting inflammation. MDPI 2023-01-04 /pmc/articles/PMC9865197/ /pubmed/36678575 http://dx.doi.org/10.3390/ph16010078 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Delbaere, Quentin
Chapet, Nicolas
Huet, Fabien
Delmas, Clément
Mewton, Nathan
Prunier, Fabrice
Angoulvant, Denis
Roubille, François
Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases
title Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases
title_full Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases
title_fullStr Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases
title_full_unstemmed Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases
title_short Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases
title_sort anti-inflammatory drug candidates for prevention and treatment of cardiovascular diseases
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865197/
https://www.ncbi.nlm.nih.gov/pubmed/36678575
http://dx.doi.org/10.3390/ph16010078
work_keys_str_mv AT delbaerequentin antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases
AT chapetnicolas antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases
AT huetfabien antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases
AT delmasclement antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases
AT mewtonnathan antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases
AT prunierfabrice antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases
AT angoulvantdenis antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases
AT roubillefrancois antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases